| abstract |
A method of treating an autoimmune disease and/or inflammatory condition in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof. The autoimmune disease and/or inflammatory condition may include, inter alia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, type-I diabetes, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, and ulcerative colitis, including refractory diseases/conditions thereof. |